Management of primary cardiac paraganglioma
- PMID: 33148444
- DOI: 10.1016/j.jtcvs.2020.09.100
Management of primary cardiac paraganglioma
Abstract
Objective: Cardiac paraganglioma is a rare tumor that most surgeons have limited experience treating. The objective of this study is to examine the management and outcomes for cardiac paraganglioma treatment when cared for by a multidisciplinary cardiac tumor team.
Methods: We reviewed our institutionally approved cardiac tumor database from March 2004 to June 2020 for cardiac paraganglioma. These prospectively collected data were retrospectively reviewed. Patient characteristics were presented for individual patients and as summary statistics. Demographic and clinical data were also reported as median and interquartile range for continuous variables and frequencies and proportions for categoric variables. Kaplan-Meier curves were used to depict the patient survival from surgery.
Results: There were 21 cases of primary cardiac paraganglioma, 19 of whom had surgical resection with 3 refusing offered surgery. Of 19 resected tumors, 13 originated from the left atrium and 6 originated from the roots of the pulmonary artery and the aorta. Complex procedures were required, including aortic and pulmonary root replacement and 8 autotransplants. All tumors had complete gross resection with no identifiable disease left behind, but 4 of these had microscopically positive margins. None of the patients had local recurrence of disease. There was 1 case of metastatic paraganglioma with death at 4 years postsurgery. Operative mortality was 10.6%. Survival from surgery was 88.2%, 71.8%, and 71.8% and 1, 5, and 10 years, respectively.
Conclusions: Cardiac paraganglioma presents a surgical challenge. Mortality and long-term survival after surgical resection are acceptable but may require complex resection and reconstruction.
Keywords: endocrine; paraganglioma; tumor.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Comment in
-
Commentary: Management of cardiac paraganglioma is a team sport.J Thorac Cardiovasc Surg. 2022 Jul;164(1):167-168. doi: 10.1016/j.jtcvs.2020.10.015. Epub 2020 Oct 27. J Thorac Cardiovasc Surg. 2022. PMID: 33220967 No abstract available.
-
Commentary: What lessons can a surgeon learn from something rare?J Thorac Cardiovasc Surg. 2022 Jul;164(1):168-169. doi: 10.1016/j.jtcvs.2020.10.032. Epub 2020 Oct 17. J Thorac Cardiovasc Surg. 2022. PMID: 33234254 No abstract available.
-
Commentary: Resection of cardiac paragangliomas: All roads lead to Texas.J Thorac Cardiovasc Surg. 2022 Jul;164(1):169-170. doi: 10.1016/j.jtcvs.2020.11.004. Epub 2020 Nov 6. J Thorac Cardiovasc Surg. 2022. PMID: 33514468 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources